| Identification | More | [Name]
FLUNIXIN MEGLUMINE | [CAS]
38677-85-9 | [Synonyms]
2-[[2-METHYL-3-(TRIFLUOROMETHYL)PHENYL]AMINO]-3-PYRIDINECARBOXYLIC ACID MEGLUMINE SALT
BANAMINE
BUTANIXIN
FLUNIXINE MEGLUMINE SALT
FLUNIXIN MEGLUMINE
FLUNIXIN MEGLUMINE SALT
Flunixin VETRANAL
FlunixinMeglumineBase
3-Pyridinecarboxylic acid, 2-2-methyl-3-(trifluoromethyl)phenylamino-
2-(2-Methyl-3-trifluoromethylanilino)nicotinic Acid
2-[[2-Methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic Acid
Sch 14714
2-[2-Methyl-3-(trifluoromethyl)phenylamino]nicotinic acid | [Molecular Formula]
C21H28F3N3O7 | [MDL Number]
MFCD01725419 | [Molecular Weight]
491.46 | [MOL File]
38677-85-9.mol |
| Safety Data | Back Directory | [Hazard Codes ]
Xi,Xn | [Risk Statements ]
R36/37/38:Irritating to eyes, respiratory system and skin .
R22:Harmful if swallowed. | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [RIDADR ]
UN2811 6.1/PG 3 | [WGK Germany ]
3
| [RTECS ]
LZ4367000
| [HS Code ]
2933399990 |
| Hazard Information | Back Directory | [Chemical Properties]
Crystalline Solid | [Uses]
Cyclooxigenase inhibitor. Anti-inflammatory; analgesic; antipyretic | [Definition]
ChEBI: A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a 2-methyl-3-(trifluoromethyl)phenylamino group. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties;
sed in veterinary medicine (usually as the meglumine salt) for treatment of horses, cattle and pigs. | [General Description]
Flunixin is classified under the group of non-steroidal anti-inflammatory drugs (NSAIDs). | [in vivo]
Flunixin meglumine (intravenous injection; 1.1 mg/kg; once) treatment inhibits the formation of exudate PGE2 and serum TXB2[1]. | Animal Model: | Male sheep injected with Carrageenan[1] | | Dosage: | 1.1 mg/kg | | Administration: | Intravenous injection; 1.1 mg/kg; once | | Result: | Inhibited Carrageenan-induced exudate PGE2 formation (Emax, 100%, IC50, <0.4 nM) and serum TXB2 generation (Emax, 100%, IC50, 17 nM) for up to 32 h. |
| [IC 50]
COX-1: 0.55 μM (IC50); COX-2: 3.24 μM (IC50) |
|
| Company Name: |
LGM Pharma
|
| Tel: |
1-(800)-881-8210 |
| Website: |
www.lgmpharma.com |
|